A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania

RATIONALE: Lithium is an effective prophylactic and anti-manic treatment in bipolar disorder; however, its use is declining through perceived poor tolerance and toxicity. Lithium inhibits inositol monophosphatase (IMPase), a probable key therapeutic mechanism. The anti-inflammatory drug, ebselen, al...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Psychopharmacology (Berl)
Main Authors: Sharpley, Ann L, Williams, Clare, Holder, Adele A, Godlewska, Beata R, Singh, Nisha, Shanyinde, Milensu, MacDonald, Orla, Cowen, Philip J
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683468/
https://ncbi.nlm.nih.gov/pubmed/32909076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00213-020-05654-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados